Colossal Biosciences, the prominent de-extinction startup, is reportedly in discussions to secure new funding at a staggering valuation between $20 billion and $30 billion. This potential capital infusion comes despite the company not yet having revived any of its target species, including the woolly mammoth. The talks raise a significant question about what investors are truly valuing in a company whose primary mission remains a long-term scientific endeavor.
A Platform Beyond De-Extinction
The firm's immense valuation appears to stem from its underlying technology platform rather than its de-extinction goals alone. Co-founded by entrepreneur Ben Lamm and Harvard geneticist George Church, Colossal leverages a powerful toolkit of gene editing, AI-driven genomics, and synthetic biology. These core competencies have applications that extend far beyond bringing back extinct animals, attracting significant investor interest.
Colossal has already begun to monetize its technology and build key partnerships, demonstrating early commercial viability. The company provides conservation technology to government bodies, including a notable $60 million investment from the UAE to establish a global genetic "BioVault". These revenue-generating activities provide a solid foundation while its more ambitious projects mature.
Generating Value Through Corporate Spinouts
A key component of Colossal's strategy involves spinning out new companies based on its proprietary research and intellectual property. Notable ventures include Form Bio, a computational biology platform, and Astromech, an AI-driven predictive modeling firm valued at $2 billion. This approach allows the company to commercialize its innovations across various independent and fundable businesses.
This spinout model effectively transforms Colossal into a synthetic biology incubator, creating a more durable and diversified investment case. By creating separate entities like Breaking, which focuses on plastic degradation, the company mitigates the high-risk nature of its central mission. This strategy showcases a clear path to generating returns from its core scientific advancements.
Investing in Future Markets
Investors are also pricing in the company's potential to create and dominate entirely new markets in the future. CEO Ben Lamm has indicated that artificial womb technology, with potential applications in human fertility, is under development and could be ready soon. This venture represents a significant expansion of the company's scope into highly lucrative healthcare sectors.
The company is also exploring future revenue from biodiversity credits, a market-based system modeled after carbon credits. Should Colossal succeed in reintroducing species and restoring ecosystems, it could generate income by selling these environmental credits. This forward-thinking approach positions the company at the forefront of an emerging bio-economy.
In summary, the potential $20 to $30 billion valuation reflects investor confidence in Colossal as a comprehensive synthetic biology platform, not just a de-extinction project. While the woolly mammoth remains its public face, the company's true value lies in its diverse commercialization strategy. This approach, encompassing spinouts, government contracts, and pioneering future markets, underpins its remarkable financial growth.
Source: Axios